---
title: "Moderna falls 4% as Rothschild Redburn downgrades on valuation concerns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297923619.md"
description: "Rothschild Redburn downgrades Moderna to Sell on valuation, raises target to $81 on positive vaccine trial data."
datetime: "2026-09-03T13:37:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297923619.md)
  - [en](https://longbridge.com/en/news/297923619.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297923619.md)
generator: "portal-rs"
---

# Moderna falls 4% as Rothschild Redburn downgrades on valuation concerns

Moderna(MRNA.US) 盘中跌**3.64%**，现报**145.315 美元**。

消息面上，Rothschild Redburn 分析师 Simon Baker 因估值问题将 Moderna 评级从持有下调至卖出。尽管基于癌症疫苗三期试验的积极结果，分析师将目标价从**40 美元**上调至**81 美元**，但其认为当前投资者对广泛采用的预期缺乏数据支撑，使得估值难以合理化。

### Related Stocks

- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)

## Related News & Research

- [Amundi Reduces Stock Holdings in Moderna, Inc. $MRNA](https://longbridge.com/en/news/298693237.md)
- [Moderna (NASDAQ:MRNA) Insider Sells $485,766.45 in Stock](https://longbridge.com/en/news/297959605.md)
- [Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It](https://longbridge.com/en/news/298134130.md)
- [Moderna Chief Legal Officer Shannon Thyme Klinger disposes of USD 485,271.45 in common shares](https://longbridge.com/en/news/297958452.md)
- [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**